Regenxbio Inc (RGNX)
16.78
-0.05
(-0.30%)
USD |
NASDAQ |
May 06, 12:27
Regenxbio Free Cash Flow: -228.37M for Dec. 31, 2023
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| December 31, 2023 | -228.37M |
| September 30, 2023 | -231.32M |
| June 30, 2023 | -235.98M |
| March 31, 2023 | -257.07M |
| December 31, 2022 | -238.21M |
| September 30, 2022 | 133.51M |
| June 30, 2022 | 127.82M |
| March 31, 2022 | 142.89M |
| December 31, 2021 | 134.70M |
| September 30, 2021 | -165.60M |
| June 30, 2021 | -146.94M |
| March 31, 2021 | -115.80M |
| December 31, 2020 | -80.93M |
| September 30, 2020 | -134.05M |
| June 30, 2020 | -123.35M |
| March 31, 2020 | -127.88M |
| December 31, 2019 | -119.42M |
| Date | Value |
|---|---|
| September 30, 2019 | -101.92M |
| June 30, 2019 | -93.01M |
| March 31, 2019 | 3.828M |
| December 31, 2018 | 91.37M |
| September 30, 2018 | 84.47M |
| June 30, 2018 | 89.82M |
| March 31, 2018 | 11.05M |
| December 31, 2017 | -65.15M |
| September 30, 2017 | -74.08M |
| June 30, 2017 | -70.54M |
| March 31, 2017 | -68.81M |
| December 31, 2016 | -56.71M |
| September 30, 2016 | -36.42M |
| June 30, 2016 | -30.85M |
| March 31, 2016 | -29.56M |
| December 31, 2015 | -23.04M |
Free Cash Flow Range, Past 5 Years
-257.07M
Minimum
Mar 2023
142.89M
Maximum
Mar 2022
-97.94M
Average
-123.35M
Median
Jun 2020
Free Cash Flow Benchmarks
| Sarepta Therapeutics Inc | -653.88M |
| Amgen Inc | 7.098B |
| Gilead Sciences Inc | 8.481B |
| AbbVie Inc | 21.89B |
| Bristol-Myers Squibb Co | 12.51B |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -40.76M |
| Cash from Investing (Quarterly) | 33.97M |
| Cash from Financing (Quarterly) | -11.96M |
| Free Cash Flow Per Share (Quarterly) | -0.9519 |
| Free Cash Flow to Equity (Quarterly) | -41.89M |
| Free Cash Flow to Firm (Quarterly) | -40.39M |
| Free Cash Flow Yield | -31.12% |